September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system), the first and only intravesical drug releasing system (iDRS) for extended delivery of a cancer drug into the bladder. This approval introduces a potentially practice-changing option for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), a population with limited treatment alternatives short of radical cystectomy.
Science Significance
INLEXZO™ transforms drug delivery by providing continuous local release of gemcitabine directly into the bladder for up to three weeks per cycle. Unlike systemic chemotherapy, this innovative device-based system combines drug and delivery technology, allowing targeted therapy with improved tolerability. Supported by the SunRISe-1 Phase 2b clinical trial, INLEXZO™ achieved 82% complete response rates in BCG-unresponsive NMIBC patients, with over 50% maintaining response for at least one year.
The scientific breakthrough lies not only in the high efficacy but also in the integration of device technology with pharmacology, opening a new era for intravesical therapies and potentially other localized cancers.
Regulatory Significance
The FDA’s approval was expedited through Breakthrough Therapy Designation, Real-Time Oncology Review, and Priority Review, underscoring the urgency of innovation in bladder cancer treatment. INLEXZO™ sets a precedent as the first intravesical system combining sustained-release chemotherapy with a simple outpatient procedure.
Advertisement
This decision reflects regulators’ increasing willingness to adopt hybrid drug-device therapies where strong clinical benefit is demonstrated. FDA’s move also acknowledges the unmet need for therapies in a cancer type that has seen little change for more than 40 years.
Business Significance
For Johnson & Johnson, INLEXZO™ represents a strategic expansion at the intersection of Innovative Medicine and MedTech. By leveraging its unique dual expertise, J&J accelerated development and delivery of a first-in-class product with significant commercial potential.
Bladder cancer affects more than half a million people globally each year, with NMIBC making up the majority of cases. Given that the current standard, BCG, fails in many patients, INLEXZO™ enters a market with substantial demand and limited options, offering J&J a strong foothold in uro-oncology.
Patients’ Significance
For patients, INLEXZO™ offers the first bladder-preserving therapy after BCG failure. Traditionally, these patients face the prospect of radical cystectomy, a life-altering surgery with significant morbidity and mortality risk. INLEXZO™ provides an outpatient-administered, non-surgical alternative that may preserve bladder function while achieving meaningful cancer control.
Patient advocacy groups, such as the Bladder Cancer Advocacy Network (BCAN), hailed the approval as a breakthrough in patient choice and quality of life. The potential to avoid or delay cystectomy is a transformative shift for thousands of patients worldwide.
Policy Significance
At the policy level, INLEXZO™ aligns with healthcare priorities of expanding access to innovative, less invasive treatments. By reducing the need for costly surgeries and long hospital stays, it supports value-based care models and could ease the economic burden associated with bladder cancer management.
FDA’s approval reinforces a growing policy emphasis on accelerated pathways for high-impact oncology innovations, particularly where drug-device combinations address urgent unmet needs. This development will likely shape future discussions on reimbursement frameworks for novel localized drug delivery platforms.
Transaction Highlights
INLEXZO™ is the first intravesical drug releasing system to win FDA approval, offering gemcitabine extended release for up to three weeks per cycle, with outpatient insertion in just minutes. Supported by the SunRISe-1 Phase 2b trial, it demonstrated 82% complete response rates and durable outcomes in patients with BCG-unresponsive NMIBC.
Johnson & Johnson’s dual expertise in pharmaceuticals and medical devices uniquely enabled this breakthrough. The FDA approval of INLEXZO™ not only delivers a new gold standard for bladder-preserving therapy but also represents a turning point in the evolution of oncology drug delivery systems.
By bridging science, regulatory innovation, business opportunity, patient benefit, and policy alignment, INLEXZO™ is set to reshape the future of bladder cancer care.
Source: Johnson & Johnson Press Release
